Skip to content

Peptides for OCD: What Oxytocin, Selank and Semax Trials Show

Peptides for OCD: the two small oxytocin trials that found no benefit, why Selank and Semax have zero OCD studies, and the FDA-approved treatments that exist.

Sebastian Hunter, Founder and EditorWritten bySebastian Hunter, Founder and EditorI'm a 42-year-old senior advisor and distance runner who came to peptides as a sceptic. I'm not a doctor: I read the research, run my own experiment and keep honest notes. Read full bio

The short version

No peptide is approved to treat obsessive-compulsive disorder (OCD), and OCD already has FDA-approved medication and evidence-based therapy. Oxytocin nasal spray has been tested in OCD, in two small controlled studies, and did not reduce obsessions or compulsions. Selank and Semax, sold online for anxiety and focus, have never been tested in OCD. Their published trials cover generalized anxiety, neurasthenia, motor neuron disease and stroke.

  • No peptide holds FDA approval for OCD. SSRIs and exposure-based therapy do.
  • Oxytocin was tested directly in OCD, in a 1992 controlled trial that found no reduction in obsessions or compulsions.
  • Selank and Semax have zero published OCD studies. Their trial record is anxiety, neurasthenia, motor neuron disease and stroke.
  • A vendor claim that any peptide treats OCD is not backed by a study I could locate.

No peptide is approved to treat obsessive-compulsive disorder, and none has published human evidence of reducing OCD symptoms. Exactly one peptide sold in this market, oxytocin, has been tested in OCD patients, and the one controlled trial with a published finding says it did not work. Selank and Semax, both marketed as anxiety and focus peptides, have never been studied in OCD. OCD already has FDA-approved medication and an evidence-based therapy. This page reports what was tested, in whom, and what it found. It is not a treatment recommendation.

Does any peptide treat OCD?

No. Nothing sold as a peptide holds an FDA-approved indication for OCD, and I could not locate a single published trial showing a peptide reduced OCD symptoms. One compound has been tested, though, and it is worth reading in detail because the result is a clean negative rather than an absence of data.

Oxytocin and OCD: what the two trials found

A 1992 double-blind, placebo-controlled trial den 1992 - den Boer JA, Westenberg HG. Oxytocin in obsessive compulsive disorder. Peptides. 1992;13(6):1083-5., in the references below gave 12 patients with OCD (nine women, three men) intranasal oxytocin spray at 18 IU per day, or placebo. No reduction in the number of obsessions or compulsive behaviors was observed in either group. To test a higher dose, two additional patients received a threefold higher dose in an open design. One showed a slight reduction in checking rituals, the other virtually none. The paper’s own conclusion is that the results do not support oxytocin as a potential anticompulsive agent.

A second, brief 1996 report Epperson 1996 - Epperson CN, McDougle CJ, Price LH. Intranasal oxytocin in obsessive-compulsive disorder. Biol Psychiatry. 1996;40(6):547-9., in the references below also tested intranasal oxytocin in OCD patients. PubMed has no abstract for it, so this page says only that it exists and what it studied, not a finding I cannot verify.

Selank, Semax and OCD: marketing versus the literature

A direct PubMed search for Selank combined with “obsessive” or “OCD” returns zero results. The same search for Semax also returns zero. Neither compound has been studied in OCD, in any species, in any published record this page could find.

Both have research elsewhere, and their trial records are narrow. See the full Selank guide and full Semax guide for the detail:

  • Selank: generalized anxiety disorder and neurasthenia.
  • Semax: motor neuron disease and stroke rehabilitation.

Marketing copy that groups anxiety-peptide claims together with OCD stretches a mechanism story across a condition nobody tested it in.

What is FDA-approved for OCD

Selective serotonin reuptake inhibitors (SSRIs) are FDA-approved for OCD. Fluvoxamine’s own FDA label states it is indicated for the treatment of obsessive compulsive disorder, based on controlled trial evidence reviewed by the agency. Structured exposure and response prevention (ERP) therapy is a standard, evidence-based treatment alongside medication. Neither is a peptide, and neither is what is sold online under an OCD-adjacent marketing claim.

Common questions

Can peptides treat OCD?

No. No peptide has FDA approval for OCD, and none has published human evidence of reducing OCD symptoms. Oxytocin is the only peptide tested in OCD patients, and the one controlled trial with published results found no benefit. Selank and Semax, both marketed for anxiety, have never been studied in OCD.

Does oxytocin help OCD?

The best evidence says no. A 1992 double-blind, placebo-controlled trial gave 12 OCD patients intranasal oxytocin (18 IU/day) or placebo. It found no reduction in obsessions or compulsions in either group. A higher, open-label dose in two more patients showed at most a slight change in one person. A second, brief 1996 report also tested intranasal oxytocin in OCD, but PubMed has no abstract for it, so I cannot summarize its findings.

Do Selank or Semax treat OCD?

There is no published study of either compound in OCD. A direct PubMed search for each returns zero results. Both have real but narrow trial records elsewhere: Selank in generalized anxiety disorder and neurasthenia, Semax in motor neuron disease and stroke rehabilitation. Marketing that implies they treat OCD is not backed by a study.

What is the FDA-approved treatment for OCD?

Selective serotonin reuptake inhibitors (SSRIs) are FDA-approved for OCD. Fluvoxamine's own FDA label, for example, states it is indicated for the treatment of obsessive compulsive disorder. Structured psychotherapy, specifically exposure and response prevention (ERP), is a standard evidence-based treatment alongside medication. Neither is a peptide.

Is oxytocin nasal spray safe to try for OCD?

The intranasal doses used in OCD and other research settings are reported as generally tolerated in trials. Being tolerated over a short trial is not the same as being safe for indefinite consumer use. The product sold online is also not the FDA-approved injectable oxytocin used in obstetrics. It is an unregulated, unverified spray with no OCD efficacy behind it.

What has actually been tested for OCD, peptide-wise?

Exactly one peptide has a documented human OCD trial record: oxytocin. It was found ineffective on its primary measures in the one trial with a published abstract. Selank and Semax have no OCD-specific research. Their evidence lies in unrelated conditions.

References (6 sources)

Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.

  1. 1.den Boer JA, Westenberg HG. Oxytocin in obsessive compulsive disorder. Peptides. 1992;13(6):1083-5.Randomised trialPMID 1494489
  2. 2.Epperson CN, McDougle CJ, Price LH. Intranasal oxytocin in obsessive-compulsive disorder. Biol Psychiatry. 1996;40(6):547-9.Randomised trialPMID 8879477
  3. 3.MacDonald E, Dadds MR, Brennan JL et al. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology. 2011;36(8):1114-26.Systematic reviewPMID 21429671
  4. 4.FDA label (DailyMed) for fluvoxamine maleate extended-release capsules - indicated for the treatment of obsessive compulsive disorder (OCD). Fetched this session.- DailyMed, US National Library of Medicinelabel
  5. 5.NCBI E-utilities esearch: Selank AND (obsessive OR OCD), zero records (queried 2026-09-27).- National Center for Biotechnology Information, US National Library of Medicinedatabase
  6. 6.NCBI E-utilities esearch: Semax AND (obsessive OR OCD), zero records (queried 2026-09-27).- National Center for Biotechnology Information, US National Library of Medicinedatabase

Keep reading

Related guides